Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CELU
$1.31
$
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Next Earnings
2026-02-25
Beta
0.801
Average Volume
Market Cap
Last Dividend
CIK
0001752828
ISIN
US1511902041
CUSIP
151190105
CEO
Robert Joseph Hariri
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
120
IPO Date
2019-08-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses | FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits. | GlobeNewsWire | 2026-02-10 08:30:00 |
| Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations | While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz | GlobeNewsWire | 2025-12-26 08:30:00 |
| Celularity Announces Closing of Financing Transactions | FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. | GlobeNewsWire | 2025-12-22 16:01:00 |
| Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision | FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly. | GlobeNewsWire | 2025-12-18 14:10:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-11 | 2026-02-11 | View Filing |
| 8-K | 2026-01-21 | 2026-01-21 | View Filing |
| 4/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4/A | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-14 | 2026-01-14 | View Filing |
| 424B3 | 2026-01-08 | 2026-01-08 | View Filing |
| EFFECT | 2026-01-07 | 2026-01-08 | View Filing |
| S-1 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| EFFECT | 2025-12-29 | 2025-12-30 | View Filing |
| 8-K | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| 4 | 2025-12-22 | 2025-12-22 | View Filing |
| S-1 | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-12-05 | 2025-12-05 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| S-8 | 2025-11-07 | 2025-11-07 | View Filing |
| DEFA14A | 2025-11-07 | 2025-11-07 | View Filing |
| ARS | 2025-11-07 | 2025-11-07 | View Filing |
| DEF 14A | 2025-11-07 | 2025-11-07 | View Filing |
| D | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-09-03 | 2025-09-02 | View Filing |
| 10-Q | 2025-08-29 | 2025-08-29 | View Filing |
| 10-Q | 2025-08-29 | 2025-08-29 | View Filing |
| SC 13G | 2025-08-27 | 2025-08-27 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| D | 2025-08-05 | 2025-08-05 | View Filing |
| D | 2025-08-05 | 2025-08-05 | View Filing |
| D | 2025-08-05 | 2025-08-05 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K/A | 2025-07-29 | 2025-07-29 | View Filing |
| SC 13D/A | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 3 | 2025-07-16 | 2025-07-16 | View Filing |
| 3 | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-06-10 | 2025-06-10 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 4/A | 2025-06-04 | 2025-06-04 | View Filing |
| 10-K/A | 2025-05-21 | 2025-05-21 | View Filing |
| 8-K | 2025-05-20 | 2025-05-20 | View Filing |
| 8-K | 2025-05-16 | 2025-05-16 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| 10-K | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-01 | 2025-05-01 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| 4 | 2025-04-15 | 2025-04-15 | View Filing |
| 4 | 2025-04-15 | 2025-04-15 | View Filing |
| 4 | 2025-04-15 | 2025-04-15 | View Filing |
| 4 | 2025-04-15 | 2025-04-15 | View Filing |
| NT 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-21 | 2025-03-21 | View Filing |
| RW | 2025-03-10 | 2025-03-10 | View Filing |
| 4/A | 2025-03-03 | 2025-03-03 | View Filing |
| 8-K | 2025-02-24 | 2025-02-24 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 8-K | 2025-02-18 | 2025-02-18 | View Filing |
| EFFECT | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| FWP | 2025-02-13 | 2025-02-13 | View Filing |
| S-1/A | 2025-02-13 | 2025-02-13 | View Filing |
| S-1 | 2025-01-30 | 2025-01-30 | View Filing |
| 4 | 2025-01-28 | 2025-01-28 | View Filing |
| SC 13D/A | 2025-01-28 | 2025-01-28 | View Filing |
| 8-K | 2025-01-27 | 2025-01-27 | View Filing |
| 8-K | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 3 | 2024-12-19 | 2024-12-19 | View Filing |
| 4 | 2024-12-19 | 2024-12-19 | View Filing |
| SC 13D/A | 2024-12-19 | 2024-12-19 | View Filing |
| 10-Q | 2024-12-06 | 2024-12-05 | View Filing |
| 8-K | 2024-12-02 | 2024-12-02 | View Filing |
| 8-K | 2024-11-29 | 2024-11-27 | View Filing |
| DEF 14A | 2024-11-19 | 2024-11-19 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 23.41% | 1.01 | 198 | 0.02 | 0.05 | 39.27 |
| Williams PercentR Strategy | 15.77% | 1.01 | 307 | 0.02 | 0.04 | 31.63 |
| Quantum Inspired Strategy | 14.53% | 1.01 | 294 | 0.02 | 0.04 | 30.39 |
| xxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | x | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |